Biogen Inc. ($BIIB) Stock Forecast: Up 5.3% Today

What is Biogen Inc.?

Biogen Inc. (NASDAQ: BIIB) is a biotechnology company focused on developing therapies for neurological and neurodegenerative diseases. The company's stock had a strong bullish movement today.

Why is Biogen Inc. going up?

BIIB stock is up 5.3% on Feb 13, 2025 18:15

• Biogen reported better-than-expected earnings for its fourth quarter, with adjusted EPS beating consensus estimates.
• Despite the positive earnings report, Biogen's 2025 EPS guidance fell short of expectations, leading to some analyst downgrades.
• The market reacted positively to Biogen's cost-cutting measures and the potential of new drugs like Leqembi, which are expected to offset revenue declines from existing products.
• Overall, the bullish movement in Biogen's stock can be attributed to the company's strong financial performance in Q4, despite some concerns about future earnings guidance.

BIIB Price Chart

BIIB Technical Analysis

BIIB News

Biogen Analysts Lower Their Forecasts After Q4 Results - Biogen ( NASDAQ:BIIB )

Biogen Inc BIIB reported better-than-expected earnings for its fourth quarter on Wednesday. The company posted fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company reported sales of $2.46 billion, up 2% year over on constant currency and 3% on a reported ...

https://www.benzinga.com/25/02/43693765/biogen-analysts-lower-their-forecasts-after-q4-results

Biogen's Q4 Earnings & Sales Beat, 2025 EPS Guidance Disappoints

BIIB's Q4 earnings and sales beat estimates. EPS guidance for 2025 falls short of expectations.

https://www.zacks.com/stock/news/2414844/biogens-q4-earnings-sales-beat-2025-eps-guidance-disappoints

Sage Therapeutics' Q4 Earnings Miss Mark, Revenues Plunge Y/Y

SAGE's earnings and revenues miss estimates in the fourth quarter of 2024. The company focuses on the commercialization of depression drug Zurzuvae.

https://www.zacks.com/stock/news/2414780/sage-therapeutics-q4-earnings-miss-mark-revenues-plunge-yy

Biogen Inc. ( BIIB ) Q4 Earnings and Revenues Surpass Estimates

Biogen (BIIB) delivered earnings and revenue surprises of 0.58% and 1.59%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2414327/biogen-inc-biib-q4-earnings-and-revenues-surpass-estimates

Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis products.

https://www.cnbc.com/2025/02/12/biogen-biib-earnings-q4-2024.html

Trending Today

Sonic (prev. FTM) ($S) Crypto Forecast: Up 8.0% Today

Injective ($INJ) Crypto Forecast: Up 5.8% Today

Memecoin ($MEME) Crypto Forecast: Down 6.1% Today

Pepe ($PEPE) Crypto Forecast: Down 5.0% Today

Maker ($MKR) Crypto Forecast: Up 5.1% Today

Golem ($GLM) Crypto Forecast: Up 31.6% Today

Optimism ($OP) Crypto Forecast: Up 5.6% Today

MANTRA ($OM) Crypto Forecast: Up 10.9% Today

NEAR Protocol ($NEAR) Crypto Forecast: Down 5.1% Today

Ethereum ($ETH) Crypto Forecast: Up 5.1% Today

Biogen Inc. Price History

25.03.2024 - BIIB Stock was down 1.9%

• Biogen posted better-than-expected earnings in the first quarter, surpassing consensus on adjusted EPS but falling short on sales, especially in the multiple sclerosis segment.
• Despite the optimistic earnings results, slow uptake of Biogen's Alzheimer's drug, Leqembi, stemming from doubts among medical professionals, has sparked concerns about future revenue growth.
• Analysts have adjusted their projections for Biogen, upholding their outperform rating on the stock despite the recent revenue dip, reflecting a mixed sentiment within the market.
• The notable downward movement in Biogen's stock today may be attributed to investors paying more attention to the decline in revenue and the challenges in adopting its key drugs rather than the positive earnings surprise.

14.01.2024 - BIIB Stock was down 7.3%

• In Q4, Biogen's sales and adjusted EPS fell short of expectations, disappointing investors.
• The decline in multiple sclerosis revenue also contributed to the bearish movement.
• A downgrade in rating and the failure to meet consensus on sales and EPS may have eroded investor confidence.
• The announcement of PRIMECAP Management increasing its stake in Biogen could offer some support, but it was insufficient to counter the overall bearish sentiment.

14.01.2024 - BIIB Stock was down 7.3%

• Several factors contribute to today's bearish movement in BIIB:
• 1. Disappointing Q4 earnings: Biogen's Q4 earnings fell below expectations, indicating strategic challenges. This has potentially decreased investor confidence, leading to selling pressure.
• 2. Rating downgrade: A downgrade to Biogen's rating has further weakened investor sentiment and contributed to the bearish movement.
• 3. Lack of positive news: While there have been mentions of Biogen's growth projections and cost-cutting measures, the absence of significant positive news or developments may have influenced the bearish market movement.
• 4. Overall market volatility: The biotechnology sector has experienced significant volatility, which could have impacted Biogen's stock price and intensified the bearish movement.
• In conclusion, the bearish movement in BIIB today can be attributed to disappointing earnings, a rating downgrade, lack of positive news, and the overall market volatility in the biotechnology sector.

29.01.2024 - BIIB Stock was down 1.7%

• BIIB stock experienced a decline greater than the overall market, finishing at $221.74, reflecting a -0.98% drop from the previous day's closing price.
• The Multiple Sclerosis market is witnessing advancements in innovative treatments, potentially affecting BIIB's competitive edge in this sector.
• Ginkgo Bioworks' acquisition of Patch Biosciences to bolster genetic medicine capabilities might have diverted attention from BIIB among investors.
• Ongoing legal investigations by Bragar Eagel & Squire, P.C. against Biogen Inc. could have contributed to the pessimistic sentiment surrounding the stock.

15.04.2024 - BIIB Stock was up 5.2%

• BIIB stock surged today due to the FDA granting fast-track designation for its Alzheimer's treatment developed in collaboration with Eisai.
• Eisai initiated the rolling submission of a Biologics License Application (BLA) for the Alzheimer's therapy to the FDA, contributing to the positive market sentiment towards BIIB.
• The advancements in BIIB's Alzheimer's treatment pipeline have increased investor confidence in the company's revenue prospects and competitive stance, resulting in a notable uptick in the stock's performance today.

31.04.2024 - BIIB Stock was up 5.3%

• BIIB stock rose following marketing authorization from the European Commission for Qalsody, a treatment for a rare genetic form of Amyotrophic Lateral Sclerosis (ALS).
• The approval of Qalsody contributed to increased investor confidence in Biogen's product pipeline and potential revenue growth.
• Despite a legal challenge in the form of a securities class action lawsuit, market sentiment was largely driven by the positive EU approval, leading to a bullish trend in BIIB stock.
• This approval highlights Biogen's dedication to addressing medical needs and expanding its range of therapies with innovative solutions.

26.06.2024 - BIIB Stock was down 8.2%

• The rejection of Biogen and Eisai's Alzheimer's drug, lecanemab, by the European Medicines Agency, citing concerns about its efficacy in early-stage Alzheimer's, led to a notable decrease in Biogen's stock value.
• The negative feedback from the Committee for Medicinal Products for Human Use (CHMP) highlighted the regulatory challenges faced by both companies, impacting investor trust in the drug's potential success.
• This rejection emphasizes the difficulties in creating effective Alzheimer's treatments and the necessity for strong clinical evidence to support approval, resulting in a pessimistic outlook on Biogen's stock.
• As attention shifts to Biogen's upcoming second-quarter earnings call, investors are eager to learn how the company plans to address this setback and navigate the regulatory environment for its Alzheimer's therapy.

26.06.2024 - BIIB Stock was down 7.3%

• The rejection of Biogen's Alzheimer's treatment, Leqembi, by the European drug regulator, citing concerns about its effectiveness and serious side effects, likely influenced the bearish market activity in BIIB stock.
• The unfavorable updates on the regulatory evaluation of Lecanemab for Early Alzheimer's Disease in the European Union may have exacerbated investor uncertainty and pushed down the stock price.
• The ongoing inquiry by Bragar Eagel & Squire, P.C. into potential claims against Biogen Inc. might have raised doubts about the company's future, affecting investor confidence and contributing to the bearish market trend.

26.06.2024 - BIIB Stock was down 8.1%

• The rejection of the Marketing Authorization Approval (MAA) for lecanemab by the Committee for Medicinal Products for Human Use (CHMP) in the European Union has significantly impacted Biogen Inc.'s stock performance.
• The negative opinion on lecanemab's effectiveness in treating early Alzheimer's disease has raised concerns among investors about the future prospects of the drug and its potential market success.
• The regulatory hurdles faced by Biogen Inc. and its partner have highlighted the uncertainties surrounding the approval and commercialization of innovative therapies in the healthcare sector.
• The market's reaction to the news reflects the sensitivity of biopharmaceutical stocks to regulatory decisions and underscores the importance of robust clinical data in gaining approval for novel treatments.

13.01.2025 - BIIB Stock was up 5.3%

• Biogen reported better-than-expected earnings for its fourth quarter, with adjusted EPS beating consensus estimates.
• Despite the positive earnings report, Biogen's 2025 EPS guidance fell short of expectations, leading to some analyst downgrades.
• The market reacted positively to Biogen's cost-cutting measures and the potential of new drugs like Leqembi, which are expected to offset revenue declines from existing products.
• Overall, the bullish movement in Biogen's stock can be attributed to the company's strong financial performance in Q4, despite some concerns about future earnings guidance.

12.01.2025 - BIIB Stock was down 5.1%

• Despite surpassing earnings and revenue projections in Q4, BIIB experienced a bearish market movement, suggesting potentially elevated market anticipations.
• The projection of profits fell below expectations despite efforts such as cost reductions and the introduction of new medications like Leqembi, indicating possible investor dissatisfaction with the company's future prospects.
• An increase in optimistic positions on BIIB through options trading potentially heightened market volatility and profit-taking, contributing to the downward trend.
• The decrease in sales of multiple sclerosis treatments and Spinraza was balanced by revenues from new drugs, but this may not have met investor expectations, resulting in the bearish market movement.

12.01.2025 - BIIB Stock was down 8.1%

• Biogen exceeded expectations with cost reduction efforts and the launch of Leqembi, but a lower profit outlook caused a decline in the stock price.
• The FDA's approval of a maintenance dosing regimen for Leqembi in Alzheimer's was a positive development, while decreased sales of multiple sclerosis drugs and Spinraza likely impacted revenue.
• Investor optimism in the options market suggests confidence in the long-term potential of Biogen's new drugs, despite short-term profit concerns.
• The forthcoming Q4 earnings report will be essential in offering more insight into the company's financial performance and the effects of new drugs on revenue.